Fucosterol is a phytosterol predominantly found in brown seaweeds such as Fucus vesiculosus and Undaria pinnatifida. Preclinical studies have investigated the potential metabolic benefits of fucosterol, particularly its effects on components of Metabolic Syndrome, such as hyperglycemia, dyslipidemia, and obesity. In vitro and animal research suggests that fucosterol may exert anti-diabetic, anti-obesity, and lipid-lowering effects, possibly through mechanisms like enhancing insulin sensitivity, modulating lipid metabolism, and reducing oxidative stress and inflammation. For example, several rodent studies have demonstrated improved glucose tolerance, lowered blood cholesterol, and reduced weight gain following fucosterol administration.

However, there is currently no robust evidence from human clinical trials directly supporting fucosterol’s efficacy for treating or preventing Metabolic Syndrome. The available data are limited to preclinical models, and the translation of these results to human health outcomes remains uncertain. There is also no strong tradition of fucosterol-rich plants being used specifically for Metabolic Syndrome in traditional medicine systems. Thus, while the scientific rationale is promising based on laboratory research, the evidence remains preliminary, and more rigorous human studies are needed to confirm its clinical relevance for Metabolic Syndrome.